Injectable Nanomedicines Market
Industry: Healthcare
Published Date: December-2018
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 173
Report ID: PMRREP25999
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Injectable Nanomedicines Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Trends
5. Key Inclusions
5.1. Nanomedicines Development Over Time
5.2. Regulatory Scenario
5.3. Disease Epidemiology
5.4. Approvals of Commercial Injectable Nanomedicines
6. North America Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
6.2.1. U.S.
6.2.2. Canada
6.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
6.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013-2017
6.4.1. Liposomes
6.4.2. Micelles
6.4.3. Nanocrystals
6.4.4. Polymeric Nanoparticles
6.4.5. Metallic Nanoparticles
6.4.6. Mesoporous Silica Nanoparticles
6.4.7. Others
6.5. Market Size (US$ Mn) Forecast By Drug Type, 2018-2026
6.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013-2017
6.6.1. Cancers
6.6.2. Central Nervous System Diseases
6.6.3. Cardiovascular diseases
6.6.4. Infection Control
6.6.5. Inflammatory Diseases
6.6.6. Others
6.7. Market Size (US$ Mn) Forecast By Application, 2018-2026
6.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
6.8.1. Hospitals
6.8.2. Ambulatory Surgical Centers
6.8.3. Clinics
6.8.4. Specialized Drugs R&D Institutes
6.8.5. Managed Care Organizations
6.9. Market Size (US$ Mn) Forecast By End User, 2018-2026
6.10. Market Attractiveness Analysis
6.10.1. By Country
6.10.2. By Drug Type
6.10.3. By Application
6.10.4. By End User
7. Latin America Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
7.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013-2017
7.4.1. Liposomes
7.4.2. Micelles
7.4.3. Nanocrystals
7.4.4. Polymeric Nanoparticles
7.4.5. Metallic Nanoparticles
7.4.6. Mesoporous Silica Nanoparticles
7.4.7. Others
7.5. Market Size (US$ Mn) Forecast By Drug Type, 2018-2026
7.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013-2017
7.6.1. Cancers
7.6.2. Central Nervous System Diseases
7.6.3. Cardiovascular diseases
7.6.4. Infection Control
7.6.5. Inflammatory Diseases
7.6.6. Others
7.7. Market Size (US$ Mn) Forecast By Application, 2018-2026
7.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
7.8.1. Hospitals
7.8.2. Ambulatory Surgical Centers
7.8.3. Clinics
7.8.4. Specialized Drugs R&D Institutes
7.8.5. Managed Care Organizations
7.9. Market Size (US$ Mn) Forecast By End User, 2018-2026
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Type
7.10.3. By Application
7.10.4. By End User
8. Europe Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
8.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013-2017
8.4.1. Liposomes
8.4.2. Micelles
8.4.3. Nanocrystals
8.4.4. Polymeric Nanoparticles
8.4.5. Metallic Nanoparticles
8.4.6. Mesoporous Silica Nanoparticles
8.4.7. Others
8.5. Market Size (US$ Mn) Forecast By Drug Type, 2018-2026
8.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013-2017
8.6.1. Cancers
8.6.2. Central Nervous System Diseases
8.6.3. Cardiovascular diseases
8.6.4. Infection Control
8.6.5. Inflammatory Diseases
8.6.6. Others
8.7. Market Size (US$ Mn) Forecast By Application, 2018-2026
8.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
8.8.1. Hospitals
8.8.2. Ambulatory Surgical Centers
8.8.3. Clinics
8.8.4. Specialized Drugs R&D Institutes
8.8.5. Managed Care Organizations
8.9. Market Size (US$ Mn) Forecast By End User, 2018-2026
8.10. Market Attractiveness Analysis
8.10.1. By Country
8.10.2. By Drug Type
8.10.3. By Application
8.10.4. By End User
9. Asia Pacific Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
9.2.1. Japan
9.2.2. China
9.2.3. India
9.2.4. Australia and New Zealand
9.2.5. Rest of Asia Pacific
9.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
9.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013-2017
9.4.1. Liposomes
9.4.2. Micelles
9.4.3. Nanocrystals
9.4.4. Polymeric Nanoparticles
9.4.5. Metallic Nanoparticles
9.4.6. Mesoporous Silica Nanoparticles
9.4.7. Others
9.5. Market Size (US$ Mn) Forecast By Drug Type, 2018-2026
9.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013-2017
9.6.1. Cancers
9.6.2. Central Nervous System Diseases
9.6.3. Cardiovascular diseases
9.6.4. Infection Control
9.6.5. Inflammatory Diseases
9.6.6. Others
9.7. Market Size (US$ Mn) Forecast By Application, 2018-2026
9.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
9.8.1. Hospitals
9.8.2. Ambulatory Surgical Centers
9.8.3. Clinics
9.8.4. Specialized Drugs R&D Institutes
9.8.5. Managed Care Organizations
9.9. Market Size (US$ Mn) Forecast By End User, 2018-2026
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Type
9.10.3. By Application
9.10.4. By End User
10. Middle East & Africa Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
10.2.1. GCC Countries
10.2.2. South Africa
10.2.3. Rest of MEA
10.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
10.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013-2017
10.4.1. Liposomes
10.4.2. Micelles
10.4.3. Nanocrystals
10.4.4. Polymeric Nanoparticles
10.4.5. Metallic Nanoparticles
10.4.6. Mesoporous Silica Nanoparticles
10.4.7. Others
10.5. Market Size (US$ Mn) Forecast By Drug Type, 2018-2026
10.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013-2017
10.6.1. Cancers
10.6.2. Central Nervous System Diseases
10.6.3. Cardiovascular diseases
10.6.4. Infection Control
10.6.5. Inflammatory Diseases
10.6.6. Others
10.7. Market Size (US$ Mn) Forecast By Application, 2018-2026
10.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
10.8.1. Hospitals
10.8.2. Ambulatory Surgical Centers
10.8.3. Clinics
10.8.4. Specialized Drugs R&D Institutes
10.8.5. Managed Care Organizations
10.9. Market Size (US$ Mn) Forecast By End User, 2018-2026
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Drug Type
10.10.3. By Application
10.10.4. By End User
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Market Structure Analysis
13.1. Market Structure by Tier of Companies
14. Competition Analysis
14.1. Competition Dashboard
14.2. Company Deep Dive
14.2.1. Merck & Co., Inc.
14.2.1.1. Overview
14.2.1.2. Product and Technology Portfolio
14.2.1.3. Production Footprint
14.2.1.4. Sales Footprint
14.2.1.5. Channel Footprint
14.2.1.6. Strategy
14.2.1.6.1. Marketing Strategy
14.2.1.6.2. Drug Strategy
14.2.1.6.3. Channel Strategy
14.2.2. Lupin
14.2.2.1. Overview
14.2.2.2. Product and Technology Portfolio
14.2.2.3. Production Footprint
14.2.2.4. Sales Footprint
14.2.2.5. Channel Footprint
14.2.2.6. Strategy
14.2.2.6.1. Marketing Strategy
14.2.2.6.2. Drug Strategy
14.2.2.6.3. Channel Strategy
14.2.3. Pacira Pharmaceuticals Inc.
14.2.3.1. Overview
14.2.3.2. Product and Technology Portfolio
14.2.3.3. Production Footprint
14.2.3.4. Sales Footprint
14.2.3.5. Channel Footprint
14.2.3.6. Strategy
14.2.3.6.1. Marketing Strategy
14.2.3.6.2. Drug Strategy
14.2.3.6.3. Channel Strategy
14.2.4. Celgene Pharmaceutical Co. Ltd.
14.2.4.1. Overview
14.2.4.2. Product and Technology Portfolio
14.2.4.3. Production Footprint
14.2.4.4. Sales Footprint
14.2.4.5. Channel Footprint
14.2.4.6. Strategy
14.2.4.6.1. Marketing Strategy
14.2.4.6.2. Drug Strategy
14.2.4.6.3. Channel Strategy
14.2.5. Amgen, Inc.
14.2.5.1. Overview
14.2.5.2. Product and Technology Portfolio
14.2.5.3. Production Footprint
14.2.5.4. Sales Footprint
14.2.5.5. Channel Footprint
14.2.5.6. Strategy
14.2.5.6.1. Marketing Strategy
14.2.5.6.2. Drug Strategy
14.2.5.6.3. Channel Strategy
14.2.6. Janssen Biotech Inc. (Sub. Johnson & Johnson Services, Inc.)
14.2.6.1. Overview
14.2.6.2. Product and Technology Portfolio
14.2.6.3. Production Footprint
14.2.6.4. Sales Footprint
14.2.6.5. Channel Footprint
14.2.6.6. Strategy
14.2.6.6.1. Marketing Strategy
14.2.6.6.2. Drug Strategy
14.2.6.6.3. Channel Strategy
14.2.7. Pfizer Inc.
14.2.7.1. Overview
14.2.7.2. Product and Technology Portfolio
14.2.7.3. Production Footprint
14.2.7.4. Sales Footprint
14.2.7.5. Channel Footprint
14.2.7.6. Strategy
14.2.7.6.1. Marketing Strategy
14.2.7.6.2. Drug Strategy
14.2.7.6.3. Channel Strategy
14.2.8. Hoffmann-La Roche Ltd.
14.2.8.1. Overview
14.2.8.2. Product and Technology Portfolio
14.2.8.3. Production Footprint
14.2.8.4. Sales Footprint
14.2.8.5. Channel Footprint
14.2.8.6. Strategy
14.2.8.6.1. Marketing Strategy
14.2.8.6.2. Drug Strategy
14.2.8.6.3. Channel Strategy
14.2.9. Teva Pharmaceutical Industries Ltd.
14.2.9.1. Overview
14.2.9.2. Product and Technology Portfolio
14.2.9.3. Production Footprint
14.2.9.4. Sales Footprint
14.2.9.5. Channel Footprint
14.2.9.6. Strategy
14.2.9.6.1. Marketing Strategy
14.2.9.6.2. Drug Strategy
14.2.9.6.3. Channel Strategy
14.2.10. Bausch & Lomb Incorporated.
14.2.10.1. Overview
14.2.10.2. Product and Technology Portfolio
14.2.10.3. Production Footprint
14.2.10.4. Sales Footprint
14.2.10.5. Channel Footprint
14.2.10.6. Strategy
14.2.10.6.1. Marketing Strategy
14.2.10.6.2. Drug Strategy
14.2.10.6.3. Channel Strategy
15. Global Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026, By Region
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013-2017
15.3. Market Size (US$ Mn) Forecast By Region, 2018-2026
15.3.1. North America
15.3.2. Latin America
15.3.3. Europe
15.3.4. Asia Pacific
15.3.5. Middle East & Africa
15.4. Market Attractiveness Analysis By Region
16. Global Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013-2017
16.2.1. Liposomes
16.2.2. Micelles
16.2.3. Nanocrystals
16.2.4. Polymeric Nanoparticles
16.2.5. Metallic Nanoparticles
16.2.6. Mesoporous Silica Nanoparticles
16.2.7. Others
16.3. Market Size (US$ Mn) Forecast By Drug Type, 2018-2026
16.4. Market Attractiveness Analysis By Drug Type
17. Global Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026, By Application
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013-2017 Orthopedic Surgery
17.2.1. Cancers
17.2.2. Central Nervous System Diseases
17.2.3. Cardiovascular diseases
17.2.4. Infection Control
17.2.5. Inflammatory Diseases
17.2.6. Others
17.3. Market Size (US$ Mn) Forecast By Application, 2018-2026
17.4. Market Attractiveness Analysis By Application
18. Global Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026, By End User
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
18.2.1. Hospitals
18.2.2. Ambulatory Surgical Centers
18.2.3. Clinics
18.2.4. Specialized Drugs R&D Institutes
18.2.5. Managed Care Organizations
18.3. Market Size (US$ Mn) Forecast By End User, 2018-2026
18.4. Market Attractiveness Analysis By End User
19. Global Injectable Nanomedicines Market Analysis 2013-2017 and Forecast 2018-2026
19.1. Market Value Share Analysis By All Segment
19.2. Y-o-Y Growth Analysis By All Segment
19.3. Absolute $ Opportunity
20. Assumptions and Acronyms Used
21. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: Parameters For Quality And Safety Evaluation Of Nanotechnology-based Medicinal Products For Biomedical Use
Table 02: Commercial Available Injectable Nanomedicines (1/3)
Table 03: Commercial Available Injectable Nanomedicines (2/3)
Table 04: Commercial Available Injectable Nanomedicines (3/3)
Table 05: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 06: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 07: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 08: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 09: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 10: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 11: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 12: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 13: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 14: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 15: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 16: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 17: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 18: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 19: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 20: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 21: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 22: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 23: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 24: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Table 25: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Region
Table 26: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 27: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Application
Table 28: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By End User
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Injectable Nanomedicines Market Value Share By Region (2018)
Figure 02: Global Injectable Nanomedicines Market Value Share, by Country (2017)
Figure 03: Global Injectable Nanomedicines Market Value Share, by Drug Type (2017)
Figure 04: Global Injectable Nanomedicines Market Value Share, by Application (2017)
Figure 05: Global Injectable Nanomedicines Market Value Share, by End User (2017)
Figure 06: North America Injectable Nanomedicines Market, Snapshot
Figure 07: North America Injectable Nanomedicines Market Value Share, by Country (2017)
Figure 08: North America Injectable Nanomedicines Market Value Share, by Drug Type (2017)
Figure 09: North America Injectable Nanomedicines Market Value Share, by Application (2017)
Figure 10: North America Injectable Nanomedicines Market Value Share, by End User (2017)
Figure 11: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013-2017
Figure 12: North America Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018-2026
Figure 13: North America Injectable Nanomedicines Market Attractiveness Analysis, By Country
Figure 14: North America Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type
Figure 15: North America Injectable Nanomedicines Market Attractiveness Analysis, By Application
Figure 16: North America Injectable Nanomedicines Market Attractiveness Analysis, By End User
Figure 17: Latin America Injectable Nanomedicines Market, Snapshot
Figure 18: Latin America Injectable Nanomedicines Market Value Share, by Country (2017)
Figure 19: Latin America Injectable Nanomedicines Market Value Share, by Drug Type (2017)
Figure 20: Latin America Injectable Nanomedicines Market Value Share, by Application (2017)
Figure 21: Latin America Injectable Nanomedicines Market Value Share, by End User (2017)
Figure 22: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013-2017
Figure 23: Latin America Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018-2026
Figure 24: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By Country
Figure 25: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type
Figure 26: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By Application
Figure 27: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By End User
Figure 28: Europe Injectable Nanomedicines Market, Snapshot
Figure 29: Europe Injectable Nanomedicines Market Value Share, by Country (2017)
Figure 30: Europe Injectable Nanomedicines Market Value Share, by Drug Type (2017)
Figure 31: Europe Injectable Nanomedicines Market Value Share, by Application (2017)
Figure 32: Europe Injectable Nanomedicines Market Value Share, by End User (2017)
Figure 33: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013-2017
Figure 34: Europe Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018-2026
Figure 35: Europe Injectable Nanomedicines Market Attractiveness Analysis, By Country
Figure 36: Europe Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type
Figure 37: Europe Injectable Nanomedicines Market Attractiveness Analysis, By Application
Figure 38: Europe Injectable Nanomedicines Market Attractiveness Analysis, By End User
Figure 39: Asia Pacific Injectable Nanomedicines Market, Snapshot
Figure 40: Asia Pacific Injectable Nanomedicines Market Value Share, by Country (2017)
Figure 41: Asia Pacific Injectable Nanomedicines Market Value Share, by Drug Type (2017)
Figure 42: Asia Pacific Injectable Nanomedicines Market Value Share, by Application (2017)
Figure 43: Asia Pacific Injectable Nanomedicines Market Value Share, by End User (2017)
Figure 44: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013-2017
Figure 45: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018-2026
Figure 46: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By Country
Figure 47: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type
Figure 48: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By Application
Figure 49: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By End User
Figure 50: Middle East & Africa Injectable Nanomedicines Market, Snapshot
Figure 51: Middle East & Africa Injectable Nanomedicines Market Value Share, by Country (2017)
Figure 52: Middle East & Africa Injectable Nanomedicines Market Value Share, by Drug Type (2017)
Figure 53: Middle East & Africa Injectable Nanomedicines Market Value Share, by Application (2017)
Figure 54: Middle East & Africa Injectable Nanomedicines Market Value Share, by End User (2017)
Figure 55: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013-2017
Figure 56: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018-2026
Figure 57: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By Country
Figure 58: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type
Figure 59: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By Application
Figure 60: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By End User
Figure 61: Global Injectable Nanomedicines Market Attractiveness Analysis, By Region
Figure 62: Global Injectable Nanomedicines Market Value Share Analysis, By Region, 2017 & 2026
Figure 63: Global Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type
Figure 64: Global Injectable Nanomedicines Market Value Share Analysis, By Drug Type, 2017 & 2026
Figure 65: Global Injectable Nanomedicines Market Attractiveness Analysis, By Application
Figure 66: Global Injectable Nanomedicines Market Value Share Analysis, By Application, 2017 & 2026
Figure 67: Global Injectable Nanomedicines Market Attractiveness Analysis, By End User
Figure 68: Global Injectable Nanomedicines Market Value Share Analysis, By End User, 2017 & 2026
Figure 69: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013-2017
Figure 70: Global Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018-2026
Figure 71: Global Injectable Nanomedicines Market Absolute $ Opportunity, 2013-2026
